Patents Represented by Attorney Jean Duvall
  • Patent number: 5721130
    Abstract: Processing of .beta.-amyloid precursor protein (.beta.APP) is monitored by detecting the secretion of a soluble .beta.APP fragment resulting from cleavage of .beta.APP at the amino-terminus of .beta.-amyloid peptide. In vivo monitoring of secretion of the .beta.APP fragment may be monitored for diagnosis and prognosis of Alzheimer's disease and other .beta.-amyloid-related diseases, while in vitro monitoring of such secretion from cultured cells may be monitored to identify inhibitors of .beta.-amyloid production. The .beta.APP fragment may be detected using antibodies and other specific binding substances which recognize a carboxy-terminal residue on the fragment.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: February 24, 1998
    Assignees: Athena Neurosciences, Inc., Eli Lilly and Company
    Inventors: Peter A. Seubert, Dale B. Schenk, Lawrence C. Fritz
  • Patent number: 5707821
    Abstract: The invention provides methods and compositions for treating neurodegeneration in mammalian cells by administering a phospholipase A2 inhibitor.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 13, 1998
    Assignee: Athena Neurosciences, Inc.
    Inventors: Russell E. Rydel, Michael S. Dappen
  • Patent number: 5200197
    Abstract: An osmotic device is disclosed comprising an exterior coat comprising an estrogenic and a progestogenic steroid that are delivered immediately as a contraceptive pair for fertility regulation in a female, and a compartment comprising an estrogenic steroid that is delivered at a controlled rate over a prolonged period of time for fertility regulation in a female.
    Type: Grant
    Filed: December 9, 1991
    Date of Patent: April 6, 1993
    Assignee: Alza Corporation
    Inventors: Jeri D. Wright, Jerry D. Childers, Brian L. Barclay, Patrick S.-L. Wong, Linda E. Atkinson